This site is intended only for all Healthcare Professionals residing in South Africa




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information



About ZAVICEFTAClinical EfficacySafety and tolerabilityThe ZAVICEFTA patientFull prescribing informationVideo Resources
Safety and tolerabilityTitle
Prescribing information available at the bottom of the page
ZAVICEFTA® has a safety and tolerability profile consistent with both cephalosporins and carbapenems 1-4

In four Phase III clinical trials, the adverse-event profile of ZAVICEFTA® was similar to that seen with either best available therapy, doripenem or meropenem 1-4

ZAVICEFTA® low potential for drug-drug interactions 5

In vitro drug combination studies with ZAVICEFTA® have demonstrated neither synergy nor antagonism with the following drugs: metronidazole, tobramycin, levofloxacin, vancomycin, linezolid and colistin and tigecycline. 
Interaction with other antimicrobial agents: Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function. Chloramphenicol is antagonistic in vitro with ceftazidime and other cephalosporins. The clinical relevance of this finding is unknown, but due to the possibility of antagonism in vivo this drug combination should be avoided.

Interaction with other medicinal products and other forms of interaction: In vitro, probenecid, a potent OAT inhibitor, inhibits avibactam uptake by 56-70 %. potentially altering the elimination of avibactam. Since
a clinical interaction trial of avibactam and probenecid has not been conducted, co-administration is not recommended.

Avibactam showed no significant inhibition of cytochrome P450 enzymes in vitro. Avibactam and ceftazidime showed no in vitro cytochrome P450 induction at clinically relevant concentrations. Avibactam and ceftazidime do not inhibit the major renal or hepatic transporters in the clinically relevant exposure range, therefore the interaction potential via these mechanisms is considered low.

Clinical data have demonstrated that there is no interaction between ceftazidime and avibactam and between ZAVICEFTA® and metronidazole.

ZAVICEFTA® has the following contraindications: 5
  • Hypersensitivity to ceftazidime, avibactam or to any of the excipients contained in ZAVICEFTA®
  • Hypersensitivity to the cephalosporin class of antibacterials.
  • Immediate and severe hypersensitivity (e.g. anaphylactic reaction) to any other type of β-lactam antibacterial medicine (e.g. penicillins, monobactams or carbapenems).
ZAVICEFTA® has some special warnings and precautions for use 5

Hypersensitivity reactions
Serious and occasionally fatal hypersensitivity reactions have been reported. In severe hypersensitivity reactions, treatment with ZAVICEFTA® must be discontinued immediately and adequate emergency measures must be initiated.

Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftazidime, to other cephalosporins or to any other type of β-lactam medicine. Caution should be used if ZAVICEFTA® is given to patients with a history of non-severe hypersensitivity to other β-lactam medicines. 

Clostridium difficile-associated diarrhoea (CDAD)
Antibacterial medicine-associated colitis and pseudo-membranous colitis have been reported with ZAVICEFTA® and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ZAVICEFTA®. Discontinuation of therapy with ZAVICEFTA® and the administration of specific treatment for Clostridium difficile should be considered. Medicines that inhibit peristalsis should not be given.

AbbreviationsReference text - Paragraph text - Lorem ipsum dolor sAE - adverse event; CDAD - Clostridium difficile-associated diarrhoea; cIAI - complicated intra-abdominal infection; cUTI - complicated urinary tract infection;  HABP - hospital-acquired bacterial pneumonia; OAT - organic anion transporterit amet, consectetur adipiscing elit. Fusce bibendum felis id turpis interdum eleifend. Ut egestas eleifend nunc sed mollis. 
ReferencesCarmeli Yet al. Lancet Infect Dis 2016;16:661-73;Mazuski JEet al. Lancet Infect Dis 2016;62:1380-9;Wagenlehner FMet al. Lancet Infect Dis 2016;63:754-62;Wagenlehner FMet al. Lancet Infect Dis 2016;63:754-62;Torres Aet al. Lancet Infect Dis 2018;18:285-95; Zavicefta® South African Approved Professional Information date of publication (21 September 2021)
View ZAVICEFTA® Prescribing information Loading
*ZAVICEFTA® South African Approved Professional Information date of publication (21 September 2021).PP-ZVA-ZAF-0029
Clinical Information Support & Services See efficacy results Loading View dosing recommendations Loading
For South Africa Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.

I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

Yes No
You are now leaving the PfizerPro South Africa website
You are leaving the South Africa HCP Portal website and being directed to a new website

This website is not controlled by South Africa HCP portal or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable